Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 8,600 Shares

Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 8,600 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $19.99, for a total transaction of $171,914.00. Following the completion of the sale, the chief executive officer now directly owns 743,675 shares in the company, valued at $14,866,063.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Atara Biotherapeutics Inc (NASDAQ ATRA) traded up $6.10 during mid-day trading on Friday, reaching $28.25. 3,693,136 shares of the company’s stock were exchanged, compared to its average volume of 860,738. The firm has a market capitalization of $832.75, a PE ratio of -8.14 and a beta of 1.27. Atara Biotherapeutics Inc has a 1 year low of $11.80 and a 1 year high of $30.40.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.05). sell-side analysts expect that Atara Biotherapeutics Inc will post -4 EPS for the current year.

Several research firms recently issued reports on ATRA. BidaskClub raised shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. Citigroup raised shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target on the stock in a research report on Wednesday, January 3rd. ValuEngine raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, December 29th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $20.00 price target on shares of Atara Biotherapeutics in a research report on Friday, October 6th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $26.00.

A number of hedge funds have recently made changes to their positions in the business. Neuberger Berman Group LLC lifted its position in Atara Biotherapeutics by 15.2% during the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock valued at $18,454,000 after buying an additional 147,061 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Atara Biotherapeutics by 1.7% during the second quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock valued at $11,842,000 after purchasing an additional 13,952 shares during the period. Artal Group S.A. raised its stake in shares of Atara Biotherapeutics by 20.0% during the third quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock valued at $9,930,000 after purchasing an additional 100,000 shares during the period. Northern Trust Corp raised its stake in shares of Atara Biotherapeutics by 12.0% during the second quarter. Northern Trust Corp now owns 298,739 shares of the biotechnology company’s stock valued at $4,183,000 after purchasing an additional 32,065 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Atara Biotherapeutics by 4.7% during the second quarter. Bank of New York Mellon Corp now owns 125,713 shares of the biotechnology company’s stock valued at $1,760,000 after purchasing an additional 5,616 shares during the period. 85.61% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 8,600 Shares” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-8600-shares.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply